CONTENTS

Section 1: Headaches
Section Editor: Debashish Chowdhury

Associate Editor: Ashish Kumar Duggal

1. A Clinical, Oculographic, and Vestibular Test Characteristics of Vestibular Migraine 1
2. TOP-PRO Study: A Randomized Double-blind Controlled Trial of Topiramate versus Propranolol for Prevention of Chronic Migraine 2
3. Randomized, Controlled Trial of Erenumab for the Prevention of Episodic Migraine in Patients from Asia, the Middle East, and Latin America: The EMPOWER Study 3
4. If Headache has any Association with Hypertension, it is Negative. Evidence from a Population-based Study in Nepal 5
5. Safety and Efficacy of Ubrogepant in Participants with Major Cardiovascular Risk Factors in Two Single-attack Phase 3 Randomized Trials: ACHIEVE I and II 6
6. Randomized, Controlled Trial of Lasmiditan over Four Migraine Attacks: Findings from the CENTURION Study 7
7 Characteristics and Outcomes of Patients with Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-induced Immune Thrombotic Thrombocytopenia 9
8. Clinical Presentation, Investigation Findings, and Treatment Outcomes of Spontaneous Intracranial Hypotension Syndrome: A Systematic Review and Meta-analysis 11
9. Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine: An Efficacy and Tolerability Comparison with Standard Prophylactic Drugs 12
10. Clinical Features of New Daily Persistent Headache: A Retrospective Chart Review of 328 Cases 13
11. An Internet-based Study on the Impact of COVID-19 Pandemic-related Lockdown on Migraine in India 14
12. Characteristics and Natural Disease History of Persistent Idiopathic Facial Pain, Trigeminal Neuralgia, and Neuropathic Facial Pain 16
13. Pediatric-onset Trigeminal Autonomic Cephalalgias: A Systematic Review and Meta-analysis 18

14. Guidelines of the International Headache Society for Clinical Trials with Neuromodulation Devices for the Treatment of Migraine 19

15. Development and Validation of a Novel Patient-reported Outcome Measure in People with Episodic Migraine and Chronic Migraine: The Activity Impairment in Migraine Diary 21

Section 2: Neuroinfections
Section Editors: Pratap Sanchetee, Samhita Panda

1. Neurosyphilis, a True Chameleon of Neurology 25

2. Neurological Disorders Seen during Second Wave of SARS-CoV-2 Pandemic from Two Tertiary Care Centers in Central and Southern Kerala 26

3. Recurrent Neurocysticercosis: Not so Rare 28

4. 6-month Neurological and Psychiatric Outcomes in 236,379 Survivors of COVID-19: A Retrospective Cohort Study using Electronic Health Records 29

5. Severe Acute Respiratory Syndrome Coronavirus 2 Encephalitis is a Cytokine Release Syndrome: Evidences from Cerebrospinal Fluid Analyses 31

6. Determinants of Brain Swelling in Pediatric and Adult Cerebral Malaria 32

7. Presenting Symptoms of Leprosy at Diagnosis: Clinical Evidence from a Cross-sectional, Population-based Study 33

8. Association between High Proviral Load, Cognitive Impairment, and White Matter Brain Lesions in Human T-lymphotropic Virus Type 1-infected Individuals 35

9. Combined Testing of Cerebrospinal Fluid Interleukin-12 (p40) and Serum C-reactive Protein as a Possible Discriminator of Acute Bacterial Neuroinfections 37

10. Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness 38

Section 3: Stroke
Section Editor: MV Padma Srivastava

Associate Editor: Ayush Agarwal

Important/Landmark Stroke Trials between June 2018 and February 2022

Thrombolysis

1. PRISMS: Effect of Alteplase versus Aspirin on Functional Outcome for Patients with Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits 41

2. EXTEND: Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke 42

3. Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion before Thrombectomy in Patients with Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial 43

Endovascular Treatment

1. BASILAR: Assessment of Endovascular Treatment for Acute Basilar Artery Occlusion via Nation-wide Prospective Registry 44
2. Aspiration Thrombectomy versus Stent Retriever Thrombectomy as First-line Approach for Large Vessel Occlusion (COMAPSS): A Multicenter, Randomized, Open-label, Blinded Outcome, Non-inferiority Trial 45
3. MR CLEAN-NO IV: A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke 46
4. Safety and Efficacy of Aspirin, Unfractionated Heparin, Both, or Neither during Endovascular Stroke Treatment (MR CLEAN-MED): An Open-label, Multicentre, Randomized Controlled Trial 47
5. Safety and Efficacy of Intensive Blood Pressure Lowering after Successful Endovascular Therapy in Acute Ischaemic Stroke (BP-TARGET): A Multicentre, Open-label, Randomized Controlled Trial 48

Secondary Prevention

1. The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) Trial: Rationale and Design 49
2. The ESUS Trials: NAVIGATE ESUS 49
3. RESPECT ESUS 50
4. PRASTRO-II: Safety and Efficacy of Prasugrel in Elderly/Low Body Weight Japanese Patients with Ischemic Stroke: Randomized PRASTRO-II 51
5. Relationship of Spontaneous Microembolic Signals to Risk Stratifcation, Recurrence, Severity, and Mortality of Ischemic Stroke: A Prospective Study 52
6. Early Prolonged Ambulatory Cardiac Monitoring in Stroke (EPACS): An Open-label Randomized Controlled Trial 52

Neuroprotection

1. ESCAPE-NA1: Efficacy and Safety of Nerinitide for the Treatment of Acute Ischemic Stroke 53
2. Randomized, Controlled, Dose Escalation Trial of a Protease-activated Receptor-1 Agonist in Acute Ischemic Stroke: Final Results of the RHAPSODY Trial 54
3. A Multicentre, Randomized, Sham-controlled Trial on Remote Ischemic Conditioning in Patients with Acute Stroke (RESIST): Rationale and Study Design 55

Stroke Recovery

1. The SHINE Randomized Clinical Trial: Intensive versus Standard Treatment of Hyperglycemia and Functional Outcome in Patients with Acute Ischemic Stroke 56
2. PROSCIS-B: Serum Anti-N-methyl-D-aspartate-receptor Antibodies and Long-term Clinical Outcome after Stroke 57
3. RESTORE BRAIN Study 58
4. Effects of Fluoxetine on Outcomes at 12 Months after Acute Stroke: Results from EFFECTS, a Randomized Controlled Trial 58

Mobile Stroke Units

1. Prospective, Multicentre, Controlled Trial of Mobile Stroke Units 59

Section 4: Epilepsy
Section Editor: Viswanathan LG, Sinha S

1. Epilepsy Outcome at Four Years in a Randomized Clinical Trial Comparing Oral Prednisolone and Intramuscular ACTH in West Syndrome 61
2. Safety and Tolerability of Transdermal Cannabidiol Gel in Children with Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial 62
3. Cost-effectiveness of Adrenocorticotropic Hormone versus Oral Steroids for Infantile Spasms 64
4. The SANTÉ Study at 10 Years of Follow-up: Effectiveness, Safety, and Sudden Unexpected Death in Epilepsy 65
5. Identifying Seizure Risk Factors: A Comparison of Sleep, Weather, and Temporal Features using a Bayesian Forecast 67
6. The SANAD II Study of the Effectiveness and Cost-effectiveness of Valproate versus Levetiracetam for Newly Diagnosed Generalized and Unclassifiable Epilepsy: An Open-label, Non-inferiority, Multicenter, Phase 4, Randomized Controlled Trial 68
7. Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial 70
8. When Should a Brain MRI be Performed in Children with New-onset Seizures? Results of a Large Prospective Trial 72
9. Improved Everyday Executive Functioning Following Profound Reduction in Seizure Frequency with Fenfluramine: Analysis from a Phase 3 Long-term Extension Study in Children/Young Adults with Dravet Syndrome 73
10. Virtual Epilepsy Clinics: A Canadian Comprehensive Epilepsy Center Experience pre-COVID and during the COVID-19 Pandemic Period 75

Section 5: Movement Disorders
Section Editors: Hrishikesh Kumar, Prashanth LK

Associate Editors: Adreesh Mukherjee, Ajith Cherian, Divya KP, Elavarasi A, Heli Shah, Jacky Ganguly, Jaslovleen Kaur, Mitesh Chandarana, Srinivas Raju, Suvorit Subhas Bhowmick

1. Effects of Statins on Dopamine Loss and Prognosis in Parkinson's Disease 79
2. Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans 80
3. Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-controlled Trial 81
4. Clinical Study of 668 Indian Subjects with Juvenile, Young, and Early Onset Parkinson's Disease 82
5. Non-invasive Vagus Nerve Stimulation Improves Clinical and Molecular Biomarkers of Parkinson's Disease in Patients with Freezing of Gait 83
6. Divergent Pallidal Pathways Underlying Distinct Parkinsonian Behavioral Deficits 84
7. Detection of α-synuclein in CSF by RT-QuIC in Patients with Isolated Rapid-eye-movement Sleep Behavior Disorder: A Longitudinal Observational Study 85
8. Predictors of Short-term Impulsive and Compulsive Behavior after Subthalamic Stimulation in Parkinson Disease 86
9. Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials 87
10. Assessment of Botulinum Neurotoxin Injection for Dystonic Hand Tremor: A Randomized Clinical Trial 88

Section 6: Ataxia
Section Editors: Pramod Kumar Pal, Achal Kumar Srivastava

Associate Editor: Divya M Radhakrishnan

1. SCA2 in the Indian Population: Unified Haplotype and Variable Phenotypic Patterns in a Large Case Series 90
2. Cognitive Impairment in Spinocerebellar Ataxia Type 12 91
3. Cognitive Impairment and its Neuroimaging Correlates in Spinocerebellar Ataxia 2 92
4. Motor and Cognitive Outcomes of Cerebello-spinal Stimulation in Neurodegenerative Ataxia 94
5. Quantitative Evaluation of Cerebellar Function in Multiple System Atrophy with Transcranial Magnetic Stimulation 95

6. Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia 96
7. Safety and Efficacy of Acetyl-DL-leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial 97
8. Developments and Validation of a Patient-reported Outcome Measure of Ataxia 99
9. Serum Neurofilament Light Chain as a Severity Marker for Spinocerebellar Ataxia 100
10. Fampridine and Acetazolamide in EA2 and Related Familial EA: A Prospective Randomized Placebo-controlled Trial 102

Section 7: Dementia and Cognition
Section Editors: Suvarna Alladi, Atanu Biswas, Faheem Arshad

Associate Editor: S Sandeep Kumar

1. Estimation of the Global Prevalence of Dementia in 2019 and Forecasted Prevalence in 2050: An Analysis for the Global Burden of Disease Study 2019 105
2. Validation of ICMR Neurocognitive Toolbox for Dementia in the Linguistically Diverse Context of India 106
3. Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer's Disease: A Meta-analysis 108
4. Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia within the GENFI Cohort 109
5. Longitudinal Changes in Hearing and Visual Impairments and Risk of Dementia in Older Adults in the United States 110
6. Sex Differences in the Genetic Architecture of Cognitive Resilience to Alzheimer's Disease 112
7. Longitudinal Study of the Effect of a 5-year Exercise Intervention on Structural Brain Complexity in Older Adults. A Generation 100 Substudy 113
8. Yoga Prevents Gray Matter Atrophy in Women at Risk for Alzheimer's Disease: A Randomized Controlled Trial 114
9. Clinical Characteristics with Inflammation Profiling of Long COVID and Association with 1-year Recovery Following Hospitalization in the UK: A Prospective Observational Study 115
10. Cognition, Behavior, and Caregiver Stress in Dementia during the COVID-19 Pandemic: An Indian Perspective 117
11. A Randomized, Double-blind, Phase 2b Proof-of-concept Clinical Trial in Early Alzheimer's Disease with Lecanemab, an Anti-Aβ Protofibril Antibody 118

Section 8: Peripheral Neuropathy
Section Editor: Tapas Kumar Banerjee

Associate Editor: Joydeep Biswas

1. Characterization of Mononeuropathy of the Lateral Cutaneous Nerve of the Calf 121
2. Mononeuritis Multiplex: An Unexpectedly Frequent Feature of Severe COVID-19 122
3. Efficacy of a Fixed Combination of Palmitoylethanolamide and Acetyl-l-carnitine in the Treatment of Neuropathies Secondary to Rheumatic Diseases 123
4. Finger Drop Sign as a New Variant of Acute Motor Axonal Neuropathy 125
5. Small Fiber Neuropathy in the Cornea of COVID-19 Patients Associated with the Generation of Ocular Surface Disease 126
6. Antecedent Infections in Guillain–Barré Syndrome Patients from South India 127
7. Motor Demyelinating Tibial Neuropathy in COVID-19 128
8. Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants: A Potential Novel Biomarker of Disease Activity 129
9. Guillain–Barré Syndrome in Patients with SARS-CoV-2: A Multicentric Study from Maharashtra, India 130
10. Epidermal Neurite Density in Skin Biopsies from Patients with Juvenile Fibromyalgia 132

Section 9: Muscle Disorders
Section Editor: Satish Khadilkar

Associate Editor: Rakhil Yadav

1. Clinical Practice with Steroid Therapy for Duchenne Muscular Dystrophy: An Expert Survey in Asia and Oceania 134
2. Deflazacort versus Prednisone/Prednisolone for Maintaining Motor Function and Delaying Loss of Ambulation: A Post-HOC Analysis from the ACT DMD Trial 135
3. Management of Adrenal Insufficiency Risk after Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations 136
4. AdipoRon, A New Therapeutic Prospect for Duchenne Muscular Dystrophy 137
5. Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy 139
6. Long-term Natural History Data in Duchenne Muscular Dystrophy Ambulant Patients with Mutations Amenable to Skip Exons 44, 45, 51, and 53 140

7. CRISPR Correction of Duchenne Muscular Dystrophy 141
8. Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy 142
9. Cardiac Management of the Patient with Duchenne Muscular Dystrophy 145
10. Respiratory Management of the Patient with Duchenne Muscular Dystrophy 146
11. Making Sense of the Clinical Spectrum of Limb-girdle Muscular Dystrophies 147
12. Plasmid-mediated Gene Therapy in Mouse Models of Limb-girdle Muscular Dystrophy 149
13. The Limb-girdle Muscular Dystrophies: Is Treatment on the Horizon? 150
14. The Effects of Resistance Exercise Training on Strength and Functional Tasks in Adults with Limb-girdle, Becker, and Facioscapulohumeral Dystrophies 152
15. Genetic Determinants of Disease Severity in the Myotonic Dystrophy Type 1 OPTIMISTIC Cohort 153
16. Efficacy and Safety of Dichlorphenamide for Primary Periodic Paralysis in Adolescents Compared with Adults 154
17. The PRINTO Evidence-based Proposal for Glucocorticoids Tapering/Discontinuation in New Onset Juvenile Dermatomyositis Patients 155
18. A Randomized, Double-blind, Placebo-controlled Trial of Infliximab in Refractory Polymyositis and Dermatomyositis 157

Section 10: Sleep Medicine
Section Editor: Manjari Tripathi

Associate Editor: Kamalesh Chakravarty

1. High-risk Characteristics for Recurrent Cardiovascular Events among Patients with Obstructive Sleep Aponea in the SAVE Study 160
2. Effects of Continuous Positive Airway Pressure on Depression and Anxiety Symptoms in Patients with Obstructive Sleep Apnoea: Results from the Sleep Apnoea Cardiovascular Endpoint Randomized Trial and Meta-analysis 161
3. Sleep Duration and Risk of Cardiovascular Events: The SAVE Study 162
4. Sleep Abnormalities and Polysomnographic Profile in Children with Drug-resistant Epilepsy 164
5. Guidelines of the Indian Society for Sleep Research (ISSR) for Practice of Sleep Medicine during COVID-19 165
6. Cognitive and Behavioral Therapy for Insomnia Increases the Use of Continuous Positive Airway Pressure Therapy in Obstructive Sleep Apnea Participants with Comorbid Insomnia: A Randomized Clinical Trial 166
7. Association of Obstructive Sleep Apnea and Cerebral Small Vessel Disease: A Systematic Review and Meta-analysis 167

8. Long-term Efficacy and Safety of Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea 169
9. Multiple Treatment Comparison in Narcolepsy: A Network Meta-analysis 170
10. Clinical and Video-polysomnographic Analysis of Rapid Eye Movement Sleep Behavior Disorder and Other Sleep Disturbances in Dementia with Lewy Bodies 171
11. Insomnia with Objective Short Sleep Duration and Risk of Incident Cardiovascular Disease and All-cause Mortality: Sleep Heart Health Study 172
12. Sleep Disturbances and Sleep Disorders in Adults Living with Chronic Pain: A Meta-analysis 174
13. Long-term Effects of an Unguided Online Cognitive Behavioral Therapy for Chronic Insomnia 175
14. Effect of CPAP Treatment of Sleep Apnea on Clinical Prognosis after Ischemic Stroke: An Observational Study 176
15. Effectiveness of an Intensive Weight-loss Program for Severe OSA in Patients Undergoing CPAP Treatment: A Randomized Controlled Trial 177
16. Effects of a 12-week Yoga versus a 12-week Educational Film Intervention on Symptoms of Restless Legs Syndrome and Related Outcomes: An Exploratory Randomized Controlled Trial 179
17. Sleepiness and Sleepiness Perception in Patients with Parkinson's Disease: A Clinical and Electrophysiological Study 180
18. The Associations of Long-time Mobile Phone Use with Sleep Disturbances and Mental Distress in Technical College Students: A Prospective Cohort Study 181

Section 11: Neuro-ophthalmology
Section Editor: Vivek Lal

Associate Editors: Aastha Takkar Kapila, Karthik Vinay Mahesh, Surbhi Mahajan, Karthik Harisankar

1. Incidentally Detected MRI Signs of Increased Intracranial Pressure 185
2. Statistical Significance of Neuroimaging Signs in Idiopathic Intracranial Hypertension 186
3. More Guts than Brains 187
4. Papilledema – 'True' or 'Pseudo'! 188
5. Diplopia: Causes and Outcomes 189
6. Pregnancy and Neuromyelitis Optica Spectrum Disorder: Important Considerations 190
7. Newer Treatment Regimens in Neuromyelitis Optica-associated Optic Neuritis 191
8. The Epidemic of Idiopathic Intracranial Hypertension 192

9. Diagnosing Idiopathic Intracranial Hypertension without Lumbar Puncture 194
10. Optic Nerve Drusen and Pseudotumor Cerebri: Dual Pathology? 195

Section 12: Autoimmune Disorders
Section Editors: Bijoy Jose, Jino Vincent, Sudheeran Kannoth

Associate Editors: Thomas Mathew, Raghunandan Nadig

1. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes 197
2. Difference in the Source of Antiaquaporin-4-immunoglobulin G and Antimyelin Oligodendrocyte Glycoprotein-immunoglobulin G Antibodies in Cerebrospinal Fluid in Patients with Neuromyelitis Optica Spectrum Disorder 198
3. Rituximab Treatment and Long-term Outcome of Patients with Autoimmune Encephalitis: Real-world Evidence from the GENERATE Registry 199
4. Characterization of LRP4/Agrin Antibodies from a Patient with Myasthenia Gravis 200
5. Autoimmune Encephalitis Resembling Dementia Syndromes 201
6. Discontinuation of Immunosuppressive Therapy in Patients with Neuromyelitis Optica Spectrum Disorder with Aquaporin-4 Antibodies 202
7. Overlapping Central and Peripheral Nervous System Syndromes in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disorders 203
8. Use and Safety of Immunotherapeutic Management of N-methyl-D-aspartate Receptor Antibody Encephalitis: A Meta-analysis 205
9. Characterization of Extracranial Giant Cell Arteritis with Intracranial Involvement and its Rapidly Progressive Subtype 206
10. Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease 207

Section 13: Rehabilitation
Section Editor: Nirmal Surya

Associate Editor: Hitav Someshwer

1. Effect of Aquatic versus Land Motor Dual Task Training on Balance and Gait of Patients with Chronic Stroke: A Randomized Controlled Trial 209
2. Early Mobilization and Quality of Life after Stroke: Findings from AVERT 210
3. Botulinum Toxin and Occupational Therapy for Writer's Cramp 212
4. A Newly Designed Intensive Caregiver Education Program Reduces Cognitive Impairment, Anxiety, and Depression in Patients with Acute Ischemic Stroke 214

5. Combining Virtual Reality Motor Rehabilitation with Cognitive Strategy Use in Chronic Stroke 216
6. Virtual Reality Rehabilitation versus Conventional Physical Therapy for Improving Balance and Gait in Parkinson's Disease Patients: A Randomized Controlled Trial 217
7. Urinary Symptoms in Patients with Parkinson's Disease and Progressive Supranuclear Palsy: Urodynamic Findings and Management of Bladder Dysfunction 218
8. The Effects of Vestibular Rehabilitation on Dizziness and Balance Problems in Patients after Traumatic Brain Injury: A Randomized Controlled Trial 220
9. Effects of High- and Low-frequency Repetitive Transcranial Magnetic Stimulation on Motor Recovery in Early Stroke Patients: Evidence from a Randomized Controlled Trial with Clinical, Neurophysiological and Functional Imaging Assessments 222
10. A Randomized Control Trial Comparing the Effects of Motor Relearning Programme and Mirror Therapy for Improving Upper Limb Motor Functions in Stroke Patients 224
11. The Use of Virtual Reality Rehabilitation for Individuals Post Stroke 225
12. A Stimulus for Eating. The Use of Neuromuscular Transcutaneous Electrical Stimulation in Patients Affected by Severe Dysphagia after Subacute Stroke: A Pilot Randomized Controlled Trial 227
13. The Effects of Aerobic Exercise on Sleep Quality Measures and Sleep-related Biomarkers in Individuals with Multiple Sclerosis: A Pilot Randomized Controlled Trial 228
14. Task-based Mirror Therapy Enhances the Upper Limb Motor Function in Subacute Stroke Patients: A Randomized Control Trial 230
15. Combined Cognitive-motor Rehabilitation in Virtual Reality Improves Motor Outcomes in Chronic Stroke: A Pilot Study 232
16. Effects of Fluoxetine on Functional Outcomes after Acute Stroke (FOCUS): A Pragmatic, Double-blind, Randomized, Controlled Trial 233

Section 14: Neurogenetics
Section Editor: Sunil Narayan

Associate Editor: KP Vinayan

Novel Therapies

1. Onasemnogene Abeparvovec Gene Therapy for Symptomatic Infantile-onset Spinal Muscular Atrophy in Patients with Two Copies of SMN2 (STR1VE): An Open-label, Single-arm, Multicentre, Phase 3 Trial 236
2. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study) 237

3. Hematopoietic Stem- and Progenitor-cell Gene Therapy for Hurler Syndrome 239
4. Treatment of Infantile-onset Spinal Muscular Atrophy with Nusinersen: Final Report of a Phase 2, Open-label, Multicentre, Dose-escalation Study 240
5. A Major Successful Early Step towards Effective Vaccination for Arresting Progression of IDH1 Grade III Glioma – Phase I Human Trial 242
6. Safety and Sustained 6 Years Effects of Treatment for Adult SMA Therapy – Phase I Trial 243
7. Long-term (1 Year) Safety and Efficacy of High-dose Pyridoxine in IGD Deficiency Epilepsy 244
8. Oral Prednisolone up to 1 mg/kg Orally Improved the Functional Status of Children with Congenital Fukuyama Myopathy (as for DMD) 246
9. In Parkinson's Disease, Yearlong Administration of Sargramostim 3 µg/kg, Stopped UPDRS Progression, Decreased Numbers and Severity of Adverse Events and Restored Peripheral Immune Function Correlating with Increased Numbers and Function of Treg: Phase 1b Study 247
10. Long 5.5-year Follow-up of Adeno-associated Vector-mediated Intracerebral Gene Therapy Encoding Human α-N-acetylglucosaminidase (rAAV2/5-hNAGLU) plus Immunotherapy in Sanfilippo B was Safe and Showed Sustained Enzyme Production 248
11. European Pompe Consortium: In Classic Infantile Pompe Disease, High ERT Dosage of 40 mg/kg/week (Alglucosidase α had Significantly Improved Survival when Compared with Patients Treated with the Standard Recommended ERT Dosage of 20 mg/kg Every Other Week. Recommend Dosage Reconsideration 249
12. In NF1, No Evidence of Neurotoxicity on 1 Year of Treatment with an MEKi and a Potential Clinical Signal of Cognitive Improvement, Supporting Future Research of Mitogen Activated Protein Kinase Inhibitor (MEKi) as a Cognitive Intervention 251

Symptomatic Therapy

1. Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial 252
2. Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-resistant Epilepsy 253

Pharmacogenomics

1. Association between COMT Methylation and Response to Treatment in Children with ADHD 254
2. Integrative Network-based Analysis Reveals Gene Networks and Novel Drug Repositioning Candidates for Alzheimer's Disease 255

Genetic Markers

1. KCNT1-related Epilepsies and Epileptic Encephalopathies: Phenotypic and Mutational Spectrum 256
2. APOE Genotype Contributes to the Heterogeneity in Rate of Clinical Progression in AD 258
3. Adult GBA Variants, Parkinsonism is Linked to a more Aggressive Motor Disease Course over 7 Years from Diagnosis in Patients. Recruiting only GBA Carriers can Reduce Trial Size by up to 65% Compared to a Trial Recruiting all Patients with PD 259
4. 1,250 plus Finnish Ageing Clinical Trial on Multidomain Interventions Facilitated LTL Maintenance among Subgroups of Older People and LTL (Telomere Length) Maintenance was Associated with more Pronounced Cognitive Intervention Benefits 261
5. Most known CSF Biomarkers of Parkinsonism Predict Cognitive Decline in PD during Follow-up but only α-syn help Dissociate it from Healthy Controls 262
6. CMT: UK CMT 6-year and US Follow-up Cohorts and Two Mouse Models—NfL Light Chain not a Helpful Biomarker to Assess Response to Therapy in Clinical Trials 263
7. Increased Copy Number of APP is Sufficient to Cause AD and CAA, with likely Earlier Onset in Case of Triplication Compared with Duplication 264
8. PME is One of the Best Genetically Defined Epilepsy Syndrome with Diagnostic Yield >80%. Using NGS Technology, Pathogenic Variants were Detected in both Established PME Genes and in Genes not Previously Associated with PME but Other Developmental Encephalopathies 265

Natural History and Clinical Tools

1. First Long-term (2-year) Systematic Study in Progression of FSHD – Slow Progress but Considerable Unpleasant Soft Symptoms 267
2. Ongoing Study Designed to Understand Natural History of Specific Congenital Muscular Dystrophy as an Essential Step for Reaching Trials Readiness 268
3. Bayesian Models Adequately Predict the Natural Evolution of Congenital (Centronuclear) Myopathy and Facilitate a Sufficiently Powerful Trial Design 269
4. Identification of Stage-dependent Progression Rates Provide Reliable Outcome Measures to Monitor Disease Progression, in all Trial Designs in Friedreich's Ataxia 271
5. In GNE Myopathy 3-year Natural History Study, Insight into the Appropriate Tools to Detect Clinically Meaningful Changes for Future Interventional Trials 272
6. 30-year Follow-up Study in 350 Patients of NF Type 2 to Guide Clinical Trial Design 273
7. RESCUE and REVERSE LHON Studies: LHON Progresses Rapidly in the First Months Following Onset during the Subacute Phase, Followed by Relative Stabilization during the Dynamic Phase 275

8. Different Rates of Progression of Disease in Subgroups of Patients with Different Deletions Amenable to Exon Skipping Therapy in Duchenne Muscular Dystrophy 276

9. Delphi-method Consensus-derived Canadian Outcome Measurement Toolkit Claimed to Improve Monitoring and Assessment of Adult SMA Patients 277

10. AI-based Model from Data of Two Largest Cohort Imaging Studies in HD TRACK-HD PREDICT-HD and Structural MRI Changes Together Predict Huntington Disease Progress 278

Genetic Screening

1. WISCOSIN Newborn Screening for SMA: 1/10000 Prevalence; both Timely SMN2 Information and SMN1 and SMN2 Confirmation as Parts of the Algorithm Facilitated Timely Clinical Follow-up, Family Counseling, and Treatment Planning 279

Prevalence Studies

1. The IPaNeMA Study: Using Clinical, CPK and GAA Fluorometric Method, Late-onset Pompe Prevalence in Academic, Tertiary Neuromuscular Practices in the United States and Canada is Estimated to be 1%, with an Equal Prevalence Rate of Pseudodeficiency Alleles 280

2. CADASIL Defining Cysteine Altering Stroke Associated NOTCH3 Variants Common in Korean Population, Around 10/1000 Compared to Rare 2–5/1, 00,000 Prevalence in West 281

Section 15: Demyelination
Section Editor: Netravathi M

1. Disease-modifying Therapies in Relapsing-remitting Multiple Sclerosis: A Systematic Review and Network Meta-analysis 284

2. Multiple Sclerosis, Disease-modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations 285

3. Prodromal Emesis in Myelin Oligodendrocyte Glycoprotein-antibody-associated Disorder 286

4. A Comparison of the Effects of Rituximab versus Other Immunotherapies for Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-associated Central Nervous System Demyelination: A Meta-analysis 287

5. Treatment of Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-associated Disease in Paediatric Patients: A Systematic Review 288

6. Distinct Patterns of Magnetic Resonance Imaging Lesions in Myelin Oligodendrocyte Glycoprotein-antibody Disease and Aquaporin-4 Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-analysis 289

7. Brain Magnetic Resonance Imaging Activity during the Year before Pregnancy can Predict Postpartum Clinical Relapses 290
8. A Randomized Study of Natalizumab Dosing Regimens for Relapsing-remitting Multiple Sclerosis 291
9. Treatment Escalation versus Immediate Initiation of Highly Effective Treatment for Patients with Relapsing-remitting Multiple Sclerosis: Data from 2 Different National Strategies 292

Section 16: Social Aspects of Neurology
Section Editor: Sudhir Shah

Associate Editors: Akanksha Jain, Zubin A Shah, Amey Bhise, Gaurav Shah, Umangkumar M Patel, Andelwar SL

1. American Academy of Neurology Position Statement: Ethical Issues in Clinical Research in Neurology 293
2. Ethical Issues in the Care of People with Dementia 295
3. Disabling Stroke in Persons already with a Disability: Ethical Dimensions and Directives 296
4. Driving and Epilepsy: Ethical, Legal, and Healthcare Policy Challenges 297
5. Patients' Views on the Ethical Challenges of Early Parkinson Disease Detection 298
6. Ethical Considerations in Chronic Brain Injury 299
7. Ethical Principles in Patient-centered Medical Care to Support Quality of Life in Amyotrophic Lateral Sclerosis 300
8. Ethical, Palliative, and Policy Considerations in Disorders of Consciousness 302
9. Neuroethics of Neuromodulation: An Update 303
10. The COVID-19 Pandemic and the Ethical Duties of the Neurologist 304
11. The Ethics of Motivational Neuro-doping in Sport: Praiseworthiness and Prizeworthiness 305
12. Challenges and Ethical Issues in the Course of Palliative Care Management for People Living with Advanced Neurologic Diseases 306
13. Reflections on Ethics and Humanity in Pediatric Neurology: The Value of Recognizing Ethical Issues in Common Clinical Practice 308
14. Drugs, Genes, and Screens: The Ethics of Preventing and Treating Spinal Muscular Atrophy 310
15. Understanding and Addressing Gender Equity for Women in Neurology 311

Index 315